New application of algin in treatment of hepatolenticular degeneration

A technology of hepatolenticular degeneration and alginate, applied in the direction of medical raw materials derived from algae, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problem that the effect cannot be satisfied and it is difficult to fundamentally prevent the disease Issues such as development and reversal of disease progression

Active Publication Date: 2021-09-28
THE AFFILIATED HOSPITAL OF QINGDAO UNIV +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

None of the above methods can achieve satisfactory results, and it is difficult to fundamentally prevent the development of the disease and reverse the progress of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of algin in treatment of hepatolenticular degeneration
  • New application of algin in treatment of hepatolenticular degeneration
  • New application of algin in treatment of hepatolenticular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1: The preparation technology of alginate.

[0041] The preparation process of alginate is as follows. The raw material of brown algae is one or more of kelp, wakame, ascophyllum, sargassum or macroalgae. After soaking, chopping, digesting, diluting, filtering, washing, calcium precipitation, hydrochloric acid It is prepared through the processes of decalcification, alkali dissolution, ethanol precipitation, filtration, drying, pulverization, and finished product.

[0042] The preparation process of alginate comprises the following steps:

[0043] (1) Soak and wash the brown algae with water, and then mix them evenly with an alkali agent to obtain a paste-like alginate; the soaking time is 2 hours, and the water consumption is 8 times the quality of the brown algae; the alkali agent includes sodium carbonate and sodium hydroxide , the dosage of the alkali agent is 25% of the quality of the brown algae, the digestion temperature is 60°C, and the digestion tim...

Embodiment 2

[0049] Example 2: Alginate can significantly promote the discharge of copper ions in the body.

[0050] What this embodiment adopts is the alginate obtained in embodiment 1.

[0051] 1. Seventy adult healthy male Kunming mice were provided by Jinan Pengyue Experimental Animal Breeding Company, SCXK (Lu) 20190003. The weight of mice is 25g~30g, SPF grade. Before the experiment, the animals were placed in an animal laboratory at 25±2°C for one week of adaptive feeding, with free access to food and water, and 12h / 12h natural light. Randomly select 10 rats as the control group and feed them with common feed. The other 60 mice were established with HLD model by copper sulfate loading diet. After 7 days of adaptive feeding, feed the feed containing copper sulfate (1g / kg) and the water of (0.185%) copper sulfate, after feeding continuously for 28 days, put the mice in metabolic cages, keep urine for 24 hours continuously, apply induction Copper content in urine by coupled plasma ...

Embodiment 3

[0065] Example 3: Alginate can improve liver function.

[0066] What this embodiment adopts is the alginate obtained in embodiment 1.

[0067] What this embodiment adopts is the data analysis obtained in embodiment 2.

[0068] After intervening with alginate for 28 days, 5 mice were taken from each group of control group, model group, positive drug control group, low-dose treatment group, middle-dose treatment group and high-dose treatment group, and injected intraperitoneally with 10% chloral hydrate (300mg / kg) anesthetize the mouse, take 1mL of blood through the heart, let it stand for 10min, centrifuge at 4000rpm for 10min, and collect the serum.

[0069] (1) ALT and AST activity: take 50 μL of the above-mentioned stored serum samples, and use a CS-800 automatic biochemical analyzer to detect liver function indicators: alanine aminotransferase (ALT, U / L), aspartate amino Transferase (AST, U / L), total protein (TP, g / L), albumin (ALB, g / L). After modeling, the activities o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of medicine research and development, and particularly relates to novel application of algin in treatment of hepatolenticular degeneration. An oral administration in-vivo animal experiment research proves that the algin can be used for complexing copper ions in an animal body, enhancing the expression of animal liver cell copper cyanin, increasing the content of serum copper cyanin, reducing the content of urine copper and liver copper and reducing the activity of serum alanine aminotransferase and aspartate aminotransferase; the hepatic fibrosis and hepatic cell apoptosis can be resisted, so that the effects of removing copper and protecting liver are achieved in the treatment of hepatolenticular degeneration. The treatment effect is good, and market application and popularization are facilitated.

Description

Technical field: [0001] The invention belongs to the field of drug research and development, in particular to the new application of algin in treating hepatolenticular degeneration (Wilson disease). Background technique: [0002] Hepatolenticular degeneration (HLD), also known as Wilson's disease, is an autosomal recessive disorder of copper metabolism. features. The worldwide incidence of HLD is 1 / 30000~1 / 100000, and the carrier of the pathogenic gene is about 1 / 90. At present, the treatment of HLD is still a comprehensive treatment, reducing the intake of copper ions by avoiding foods high in copper. [0003] At present, there are two main types of drugs that use copper-dispelling drugs to drive copper and prevent copper absorption. One is complexing agents, which can strongly promote the excretion of copper ions in the body, such as penicillamine, sodium dimercaptosulfonate, dimercaptobutane The second is to prevent the intestinal absorption of exogenous copper, such a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61K36/03A61P1/16A61P3/00A61P25/00A61P39/02C08B37/00C08B37/04
CPCA61K31/715A61K36/03A61P1/16A61P3/00A61P25/00A61P39/02C08B37/0063C08B37/0084C08B37/0003Y02A50/30
Inventor 郭云良张国防刘英娟王发合葛科立孙占一张清华
Owner THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap